Embedded Files
DelveInsight’s “Menin Inhibitors– Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the Menin, historical and forecasted epidemiology as well as the Menin inhibitor market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.
Unlock detailed insights into the Menin Inhibitors Market by downloading the comprehensive report from DelveInsight @ Menin Inhibitors Market
Key Takeaways from the Menin Inhibitors Market Report
As per the analysis, the risk of AML increases with age, especially after 65, due to genetic mutations like KMT2A translocations or NPM1 mutations.
According to DelveInsight, in 2024, the incident population of acute myeloid leukemia in the United States was found to be around 21,250, with more males affected than females.
According to the American Cancer Society, AML is more common in older adults, with a median age at diagnosis of 68 years.
According to the Leukemia & Lymphoma Society, AML accounts for about 1% of all cancers, with subtypes like KMT2A-rearranged AML representing a significant unmet need.
The leading Menin Inhibitors Companies such as Syndax, Kura Oncology, Sumitomo Pharma America, Johnson & Johnson, and others.
Promising Menin Inhibitors Therapies such as REVUFORJ (revumenib), ziftomenib, enzomenib (DSP-5336), bleximenib (JNJ-75276617), and others.
Gain a competitive edge in the Menin Inhibitors Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Menin Inhibitors Drugs Market
Menin Inhibitors Epidemiology Segmentation in the 7MM
Total Cases of Selected Indications for Menin Inhibitor
Total Eligible Patient Pool of Selected Indications for Menin Inhibitor
Total Treated Cases of Selected Indications for Menin Inhibitor
Menin Inhibitors Treatment Market The primary treatment for AML includes chemotherapy, targeted agents, and stem cell transplants. Menin inhibitors represent a breakthrough for KMT2A-rearranged and NPM1-mutant AML, inhibiting menin-KMT2A interactions to suppress leukemogenic transcription. Recent approvals like REVUFORJ (2024) mark a shift toward precision oncology, focusing on genetically defined subtypes.
Menin Inhibitors Market Insights AML is a severe hematologic malignancy with no cure, serving as a risk factor for numerous complications. While there is no established cure, genetic testing is available to identify mutations, and treatment involves oral inhibitors, alongside chemotherapy and transplants. Menin inhibitors, the most innovative targeted treatment, disrupt oncogenic pathways to improve outcomes.
Discover key developments and opportunities in the Menin Inhibitors Market. Click here to learn more from DelveInsight's latest report @ Menin Inhibitors Market Size
Menin Inhibitors Marketed Drugs
REVUFORJ (revumenib): Syndax In November 2024, the US Food and Drug Administration approved REVUFORJ (revumenib) for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. REVUFORJ is the first menin inhibitor approved for use in the United States that targets the menin-KMT2A interaction. Menin inhibitors are targeted treatments for specific subtypes of AML.
Ziftomenib: Kura Oncology In June 2025, the US FDA accepted Kura Oncology’s NDA for ziftomenib, with Priority Review and a PDUFA date of November 30, 2025. Ziftomenib is an oral inhibitor of menin-KMT2A for the treatment of relapsed/refractory AML with NPM1 mutations. It provides a targeted approach for genetically defined AML.
Menin Inhibitors Emerging Drugs
Enzomenib (DSP-5336) - Sumitomo Pharma America Enzomenib (DSP-5336), an oral menin inhibitor being developed by Sumitomo Pharma America. The drug is currently in Phase II of development. It has received Fast Track and Orphan Drug Designations for acute leukemia, showing activity in relapsed/refractory cases.
Bleximenib (JNJ-75276617) - Johnson & Johnson Johnson & Johnson's bleximenib (JNJ-75276617) is a menin inhibitor in Phase II trials for relapsed/refractory AML. It targets menin-KMT2A interactions, with potential for combination therapies.
Other novel emerging drugs in the Menin Inhibitors treatment market in different clinical trial phases include - REVUFORJ (revumenib): Syndax, ziftomenib: Kura Oncology, enzomenib (DSP-5336): Sumitomo Pharma America, bleximenib (JNJ-75276617): Johnson & Johnson, and others.
Menin Inhibitors Market Outlook The Menin Inhibitors Market is a competitive landscape with targeted therapies entering the market. The oncology drugs market is moderately fragmented, with significant players launching novel pharmaceuticals. The market competitors are developing not only novel inhibitors but also diagnostic tools for mutation detection. The expansion of the healthcare sector and favorable regulatory support are fueling the growth of the menin inhibitors market.
Download DelveInsight's Menin Inhibitors Market report today and stay ahead in this rapidly evolving field. @ Menin Inhibitors Clinical Trials
Scope of the Menin Inhibitors Market Report
Coverage- Global
Study Period- 2020-2034
Menin Inhibitors Companies- Syndax, Kura Oncology, Sumitomo Pharma America, Johnson & Johnson, and others.
Menin Inhibitors Therapies- REVUFORJ (revumenib), ziftomenib, enzomenib (DSP-5336), bleximenib (JNJ-75276617), and others.
Menin Inhibitors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Menin Inhibitors Unmet Needs, KOL's views, Analyst's views, Menin Inhibitors Market Access and Reimbursement
Download the report to understand which factors are driving Menin Inhibitors Market Trends @ Menin Inhibitors Market Trends
Table of Content
1 Key Insights
2 Executive Summary of Global Messenger RNA
3 Competitive Intelligence Analysis for Global Messenger RNA
4 Global Messenger RNA Market Overview at a Glance
5 Global Messenger RNA Disease Background and Overview
6 Patient Journey
7 Global Messenger RNA Epidemiology and Patient Population
8 Treatment Algorithm Current Treatment and Medical Practices
9 Global Messenger RNA Unmet Needs
10 Key Endpoints of Global Messenger RNA Treatment
11 Global Messenger RNA Marketed Products
12 Global Messenger RNA Emerging Therapies
13 Global Messenger RNA Seven Major Market Analysis
14 Attribute Analysis
15 7MM Market Outlook
16 Access and Reimbursement Overview
17 KOL Views
18 Market Drivers
19 Market Barriers
20 Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
Page updated
Google Sites
Report abuse